Similar safety results of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) from a phase III trial in patients (pts) with previously untreated advanced gastric cancer (AGC)

被引：0
|
作者：
Kang, Y. K.
Kang, W. K.
Shin, D. B.
Chen, J.
Xiong, J.
Wang, J.
Lichinitser, M.
Salas, M. P.
Suarez, T.
Santamaria, J.
机构：
[1] Asan Med Ctr, Dept Internal Med, Seoul, South Korea
[2] Samsung Med Ctr, Dept Internal Med, Ilwon Dong, South Korea
[3] Gachon Med Sch, Gil Med Ctr, Dept Internal Med, Guwal Dong, South Korea
[4] Jiangsu Canc Hosp, Jiangsu, Peoples R China
[5] 1st Affiliated Hosp, Jianxi Med Coll, Jianxi, Peoples R China
[6] Shanghai Changzheng Hosp, Shanghai, Peoples R China
[7] Russian Canc Res Ctr, Blokhin Canc Res Ctr, Moscow, Russia
[8] Hosp Sabogal, Lima, Peru
[9] Ctr Med Pensiones, Yucatan, Mexico
[10] Inst Oncol Nacl, Ancon, Panama
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：205 / 205
页数：1
相关论文
共 50 条
  • [31] Interim safety results from a phase II/III trial with 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/oesophagogastric junction (OGJ) cancer: A study of the AIO.
    Koock, Ulrike
    Pauligk, Claudia
    Luley, Kim Barbara
    Mayer, Frank
    Schulmann, Karsten
    Homann, Nils
    Schmalenberg, Harald
    Hozaeel, Wael
    Hofheinz, Ralf
    Probst, Stephan
    Mahlberg, Rolf
    Koenigsmann, Michael
    Haag, Georg Martin
    Meiler, Johannes
    Prasnikar, Nicole
    Behringer, Dirk M.
    Trojan, Jorg
    Egger, Matthias
    Jaeger, Elke
    Al-Batran, Salah-Eddin
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer
    Pera, M.
    Gallego, R.
    Montagut, C.
    Martin-Richard, M.
    Iglesias, M.
    Conill, C.
    Reig, A.
    Balague, C.
    Petriz, L.
    Momblan, D.
    Bellmunt, J.
    Maurel, J.
    ANNALS OF ONCOLOGY, 2012, 23 (03) : 664 - +
  • [33] A PHASE III STUDY COMPARING LAROTAXEL TO 5-FU (CONTINUOUS INTRAVENOUS 5-FU OR CAPECITABINE) IN PATIENTS WITH ADVANCED PANCREATIC CANCER (APC) PREVIOUSLY TREATED WITH A GEMCITABINE CONTAINING REGIMEN
    Van Cutsem, E.
    Macarulla, T.
    Van Laethem, J.
    Couture, F.
    Peeters, M.
    Hoff, Gehn M.
    Roman, L.
    Lequesne, L.
    Charpentier, E.
    Conroy, T.
    ANNALS OF ONCOLOGY, 2010, 21 : 12 - 13
  • [34] Preoperative low dose continuous infusion of 5-fluorouracil (5-FU) with cisplatin for potentially unresectable advanced gastric cancer (AGC) with extensive lymph node metastasis: a phase II study
    Chin, KC
    Imazu, HI
    Mochiki, EM
    Tokunaga, AT
    Hosoya, YH
    Tsujitani, ST
    Nakajima, TN
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 251 - 252
  • [35] Final safety findings from a randomized phase III trial of capecitabine plus oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer.
    Schmoll, H. J.
    Tabernero, J.
    Nowacki, M.
    Maroun, J.
    Price, T.
    Lim, R.
    Van Cutsem, E.
    De Braud, F.
    Haller, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 163S - 163S
  • [36] Phase III trial of adjuvant capecitabine/cisplatin (XP) versus capecitabine/cisplatin/RT (XPRT) in resected gastric cancer with D2 nodal dissection (ARTIST trial): Safety analysis
    Lee, J.
    Kang, W.
    Lim, D.
    Park, J.
    Park, Y.
    Lim, H.
    Sohn, T.
    Noh, J.
    Bae, J.
    Kim, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [37] Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer
    Rao, S
    Cunningham, D
    Hawkins, RE
    Hill, ME
    Smith, D
    Daniel, F
    Ross, PJ
    Oates, J
    Norman, AR
    BRITISH JOURNAL OF CANCER, 2005, 92 (09) : 1650 - 1654
  • [38] Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer
    S Rao
    D Cunningham
    R E Hawkins
    M E Hill
    D Smith
    F Daniel
    P J Ross
    J Oates
    A R Norman
    British Journal of Cancer, 2005, 92 : 1650 - 1654
  • [39] Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
    Kang, Y. -K.
    Kang, W. -K.
    Shin, D. -B.
    Chen, J.
    Xiong, J.
    Wang, J.
    Lichinitser, M.
    Guan, Z.
    Khasanov, R.
    Zheng, L.
    Philco-Salas, M.
    Suarez, T.
    Santamaria, J.
    Forster, G.
    McCloud, P. I.
    ANNALS OF ONCOLOGY, 2009, 20 (04) : 666 - 673
  • [40] Efficacy and tolerability of bevacizumab (BEV) plus capecitabine and cisplatin (XP) in Chinese patients (pts) with locally advanced or metastatic gastric/gastroesophageal junction cancer (AGC): Results from the AVATAR study.
    Shen, Lin
    Li, Jin
    Xu, Jian-Ming
    Pan, Hong-Ming
    Dai, Guanghai
    Qin, Shukui
    Wang, Liwei
    Wang, Jinwan
    Yang, Zhenzhou
    Shu Yongqian
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
12345